financetom
Business
financetom
/
Business
/
Rexford Industrial Realty Signs 657,000 Square Feet of Leases in Q4
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Rexford Industrial Realty Signs 657,000 Square Feet of Leases in Q4
Nov 15, 2024 12:57 PM

10:11 AM EST, 11/14/2024 (MT Newswires) -- Rexford Industrial Realty ( REXR ) said Thursday it signed about 657,000 square feet of leases in Q4, including 422,000 square feet in renewals and 235,000 square feet in new leases.

The company said its lease renewals and new leases achieved rental rate increases of 80% on a net effective basis and 60% on a cash basis over previous rents. Average annual rent escalations for the leases signed to date in the quarter were 3.9%, it added.

Rexford said its same property portfolio reported an average occupancy of 96.8% year-to-date and an ending occupancy of 95.9% as of Oct. 31, aligning with Q3 guidance.

Price: 41.56, Change: -0.30, Percent Change: -0.72

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Sage Therapeutics Says Biogen Discontinues Collaboration on Sage-324 Program
Sage Therapeutics Says Biogen Discontinues Collaboration on Sage-324 Program
Oct 3, 2024
07:43 AM EDT, 09/26/2024 (MT Newswires) -- Sage Therapeutics ( SAGE ) said Thursday that Biogen (BIIB) has terminated its rights under the partnership and license agreement with the company for the Sage-324 program, effective Feb. 17. Sage said it will resume full ownership of the Sage-324 asset after termination. The companies will continue to collaborate on Zurzuvae, a US...
Pfizer withdraws sickle cell disease treatment on risk of complication, death
Pfizer withdraws sickle cell disease treatment on risk of complication, death
Oct 3, 2024
(Reuters) -U.S. drugmaker Pfizer said on Wednesday it was withdrawing its sickle cell disease treatment Oxbryta from all markets where it is approved, citing risks of a painful complication and deaths. Pfizer bought Oxbryta, also known as voxelotor, as part of its $5.4 billion buyout of Global Blood Therapeutics in 2022. It reported $328 million in revenues from the therapy...
AstraZeneca Says FDA Approved Tagrisso as Treatment of Specific Type of Non-Small Cell Lung Cancer in Adults
AstraZeneca Says FDA Approved Tagrisso as Treatment of Specific Type of Non-Small Cell Lung Cancer in Adults
Oct 3, 2024
07:38 AM EDT, 09/26/2024 (MT Newswires) -- AstraZeneca ( AZN ) said Thursday that the US Food and Drug Administration approved Tagrisso as treatment of adult patients with a specific type of non-small cell lung cancer whose disease has not progressed after platinum-based chemoradiation therapy. The approval was based on data from a phase 3 trial, which showed that Tagrisso...
Market Chatter: Spirit AeroSystems to Begin Furloughs in 3 Weeks Over Boeing Strike
Market Chatter: Spirit AeroSystems to Begin Furloughs in 3 Weeks Over Boeing Strike
Oct 3, 2024
07:42 AM EDT, 09/26/2024 (MT Newswires) -- Spirit AeroSystems ( SPR ) , Boeing's ( BA ) fuselage supplier for the 737 Max, could begin furloughing employees in three weeks if the aerospace company fails to end a strike in Washington state, the Financial Times reported Thursday, citing an industry source. For now, the company is using the labor stoppage...
Copyright 2023-2026 - www.financetom.com All Rights Reserved